Survodutide
GLP-1 / Glucagon Dual AgonistPhase 3 (SYNCHRONIZE trials)Also known as: BI 456906, Boehringer GLP-1/glucagon
Survodutide (BI 456906) is a once-weekly subcutaneous dual GLP-1 / glucagon receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. As of 2026 it is in Phase 3 clinical trials (SYNCHRONIZE program) for obesity and metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH).
Overview
At A Glance
Dual receptor agonism: simultaneously activates the GLP-1 receptor (suppressing appetite, slowing gastric emptying, improving glucose-dependent insulin secretion) AND the glucagon receptor (raising basal energy expenditure and stimulating hepatic lipolysis). The glucagon arm diff…
Overview
Survodutide (BI 456906) is a once-weekly subcutaneous dual GLP-1 / glucagon receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. As of 2026 it is in Phase 3 clinical trials (SYNCHRONIZE program) for obesity and metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). Reported Phase 2 weight-loss results from late 2024 trials approached 19% body-weight reduction at the highest dose, placing it in the same outcome tier as Eli Lilly's retatrutide. Unlike pure GLP-1 agonists (semaglutide, tirzepatide's GLP-1 component), survodutide's glucagon agonism is hypothesized to drive higher resting energy expenditure and direct hepatic lipid mobilization - important mechanisms for MASH resolution where weight loss alone is insufficient.
Potential Research Fields
Chemical Information
IUPAC Name
Not yet available
CAS Number
Not yet available
Molecular Formula
C-rich peptide (sequence not publicly disclosed)
Molecular Mass
Not yet available
Dosing & Protocols
Unlock Dosing Protocols
Free account gets you:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
2,800+ researchers already in
Research
Unlock Research Data
Free account gets you:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
2,800+ researchers already in
Interactions
Contraindications
Personal or family history of medullary thyroid carcinoma (MTC) or MEN2 syndrome. Pregnancy and breastfeeding. Active pancreatitis. Severe gastroparesis or active inflammatory bowel disease.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
No listings found for Survodutide.
Research Score
61 PubMed studies
Quality Indicators
Data Completeness
75%Research Credibility
Well-researched compound
Quick Facts
Half-Life
~140-150 hours (weekly dosing supported)
Administration
Subcutaneous
Trial Phase
Phase 3 (SYNCHRONIZE trials)
Safety Profile
Common Side Effects
- • Nausea (dose-dependent)
- • Vomiting
- • Diarrhea
- • Decreased appetite
- • Injection site reaction
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
What is Survodutide used for in research?
Survodutide (BI 456906) is a once-weekly subcutaneous dual GLP-1 / glucagon receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. As of 2026 it is in Phase 3 clinical trials (SYNCHRONIZE program) for obesity and metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). Reported Phase 2 weight-loss results from late 2024 trials approached 19% body-weight reduction at the highest dose, placing it in the same outcome tier as Eli Lilly's retatrutide.
Unlike pure GLP-1 agonists (semaglutide, tirzepatide's GLP-1 component), survodutide's glucagon agonism is hypothesized to drive higher resting energy expenditure and direct hepatic lipid mobilization - important mechanisms for MASH resolution where weight loss alone is insufficient.
What forms does Survodutide come in?
Survodutide is available in vials, capsules, and sprays forms.
How much does Survodutide cost?
Pricing varies by vendor and form.
How do I compare Survodutide vendors?
Compare prices, payment methods, shipping, and COA scores across 0 vendors.
Research Tools
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.
